The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models [Letter]

Slamet Wardoyo1 Department of Environmental Health, Poltekkes Kemenkes Surabaya, Surabaya, IndonesiaCorrespondence[email protected]

https://orcid.org/0000-0003-3936-1893

Muhammad Arief Fadillah2 Department of Medical Laboratory Technology, Poltekkes Kemenkes Banten, Tangerang, Indonesia

Hamtini2 Department of Medical Laboratory Technology, Poltekkes Kemenkes Banten, Tangerang, Indonesia

"The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models [Letter]." Breast Cancer: Targets and Therapy, , pp. 953–954

Disclosure

The author(s) report no conflicts of interest in this communication.

The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models [Letter]

Information for

Open access

Opportunities

Help and information

The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models [Letter]

Disclosure

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature